이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Merck 관리

관리 기준 확인 3/4

Merck's CEO는 Rob Davis, Apr2021 에 임명되었습니다 의 임기는 3.17 년입니다. 총 연간 보상은 $ 20.27M, 7.9% 로 구성됩니다. 7.9% 급여 및 92.1% 보너스(회사 주식 및 옵션 포함). 는 $ 44.57M 가치에 해당하는 회사 주식의 0.014% 직접 소유합니다. 44.57M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 4.8 년입니다.

주요 정보

Rob Davis

최고 경영자

US$20.3m

총 보상

CEO 급여 비율	7.9%
CEO 임기	3.2yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

May 22

Recent updates

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Jun 10

Merck Stock: Still Discounted To Graham P/E

May 29

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

May 22

CEO 보상 분석

Rob Davis 의 보수는 Merck 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

보상 대 시장: Rob 의 총 보상 ($USD 20.27M )은 US 시장( $USD 13.50M ).

보상과 수익: Rob 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Rob Davis (57 yo)

3.2yrs

테뉴어

US$20,273,287

보상

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Robert Davis	Chairman	3.2yrs	US$20.27m	0.014% $ 45.2m
Caroline Litchfield	Executive VP & CFO	3.2yrs	US$8.30m	0.0020% $ 6.6m
Richard DeLuca	Executive VP & President of Merck Animal Health	12.8yrs	US$6.20m	0.0060% $ 19.7m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	14.6yrs	US$6.24m	0.0062% $ 20.4m
Dean Li	Executive VP & President of Merck Research Laboratories	6.6yrs	US$9.78m	0.0018% $ 6.0m
Dalton Smart	Senior VP of Finance	less than a year	데이터 없음	0.00017% $ 558.3k
David Williams	Executive VP and Chief Information & Digital Officer	no data	데이터 없음	0.00078% $ 2.6m
Peter Dannenbaum	Vice President of Investor Relations	4.8yrs	데이터 없음	데이터 없음
Jennifer Zachary	Executive VP & General Counsel	6.2yrs	US$5.90m	0.0011% $ 3.8m
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	3.2yrs	데이터 없음	0.00020% $ 656.9k
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	2.8yrs	데이터 없음	데이터 없음
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: MRK 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Robert Davis	Chairman	2.9yrs	US$20.27m	0.014% $ 45.2m
Pamela Craig	Independent Director	8.8yrs	US$400.00k	0.000070% $ 229.9k
Patricia Russo	Independent Director	28.8yrs	US$360.00k	0.00052% $ 1.7m
Thomas Glocer	Independent Lead Director	16.6yrs	US$430.10k	0.00020% $ 656.9k
Risa Lavizzo-Mourey	Independent Director	4.1yrs	US$365.00k	0.000040% $ 131.4k
Douglas Baker	Independent Director	2.1yrs	US$347.64k	0.000040% $ 131.4k
Inge Thulin	Independent Director	6.3yrs	US$340.00k	0% $ 0
Stephen Mayo	Independent Director	3.3yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	4.3yrs	US$350.00k	0.000020% $ 65.7k
Christine Seidman	Independent Director	4.3yrs	US$350.00k	0% $ 0
Paul Rothman	Independent Director	8.8yrs	US$380.00k	0% $ 0
Mary Coe	Independent Director	5.3yrs	US$342.36k	0% $ 0

4.8yrs

평균 재임 기간

65.5yo

평균 연령

경험이 풍부한 이사회: MRK 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Merck 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

Insider exercised options to buy US$1.8m worth of stock.

Recent updates

Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma

Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

First quarter dividend of US$0.77 announced

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Eyebiotech Limited for $3 billion.

Merck Declares Dividend for the Third Quarter of 2024, Payable on July 8, 2024

Merck Stock: Still Discounted To Graham P/E

Merck Announces Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy

Insider exercised options to buy US$1.8m worth of stock.

Merck Q1: There's Still Room For Growth

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령